What is Invizius?
Invizius Limited is a biotechnology firm dedicated to developing novel treatments aimed at suppressing unwanted innate immune responses. The company's initial focus is on mitigating the severe inflammatory effects associated with dialysis, a critical area for patients undergoing this life-sustaining treatment. The company's current lifecycle stage, indicated by its enterprise-level funding, suggests a significant push towards clinical validation and market entry.
How much funding has Invizius raised?
Invizius has raised a total of $8.6M across 2 funding rounds:
Series A
$7.4M
Other Financing Round
$1.2M
Series A (2021): $7.4M with participation from Downing Ventures, Old College Capital, Scottish Enterprise, Dr. Jonathan Milner, Solvay Ventures, Mercia Group, and Calculus Capital
Other Financing Round (2024): $1.2M led by Calculus Capital and Mercia Ventures
Key Investors in Invizius
Downing Ventures
Downing Ventures is an evergreen fund that invests in seed to Series A companies, with a focus on technology sectors including Healthcare and Deep Tech. They are known for their potential for follow-on investments.
Scottish Enterprise
Scottish Enterprise is the national economic development agency of the Scottish Government, established to foster business growth and innovation within Scotland.
Calculus Capital
Calculus Capital is an investment manager specializing in tax-efficient growth capital for UK smaller companies, focusing on technology, healthcare, and creative industries.
What's next for Invizius?
The recent major strategic investment positions Invizius for accelerated growth and the advancement of its therapeutic pipeline. This capital infusion is expected to fuel further research and development, potentially enabling the company to move closer to human trials and regulatory submissions. The strategic nature of this financing suggests a strong belief from investors in Invizius's technology and its potential to address significant unmet medical needs in immune response modulation.
See full Invizius company page
